Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $608.2 million as the latest value for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity fell 29.84% year-over-year to $608.2 million; the TTM value through Mar 2026 reached $2.9 billion, down 21.01%, while the annual FY2025 figure was $715.7 million, 21.2% down from the prior year.
  • Liabilities and Shareholders Equity hit $608.2 million in Q1 2026 for Viking Therapeutics, down from $715.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $967.5 million in Q1 2024 and bottomed at $150.9 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $560.8 million, with a median of $608.2 million recorded in 2026.
  • Year-over-year, Liabilities and Shareholders Equity skyrocketed 541.19% in 2024 and then decreased 29.84% in 2026.
  • Viking Therapeutics' Liabilities and Shareholders Equity stood at $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then skyrocketed by 146.5% to $908.3 million in 2024, then decreased by 21.2% to $715.7 million in 2025, then decreased by 15.02% to $608.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $608.2 million, $715.7 million, and $739.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.